Bausch Health Companies Azioni (NYSE: BHC)

Ultime notizie per Bausch Health Companies (NYSE:BHC) Azioni

Bausch Health Companies

Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum revenue from the Bausch + Lomb segment.

Bausch Health Cos

Bausch Health Companies Inc. Common Stock

Bausch Health Companies Inc

BillionHappiness

BENCHMARK HLDGS PLC by Benchmark Hldgs PLC

Benchmark Holdings PLC

<ul>
<li>BNT327, BioNTech's PD-L1xVEGF-A bispecific antibody, is a clinically advanced investigational immunotherapy candidate with the potential to surpass current checkpoint inhibitor outcomes and set a new standard of care in multiple tumor types</li>
<li>The co-development and co-commercialization collaboration with a 50/50 profit/loss split will leverage both partners' expertise, resources and global footprint to accelerate BNT327's path towards potential regulatory approvals and market launches</li>
<li>BioNTech and Bristol Myers Squibb will jointly execute a broad clinical development program to evaluate and advance BNT327 across numerous solid tumor types</li>
</ul>
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.biontech.com%2Fen&amp;esheet=54263388&amp;newsitemid=20250602838823&amp;lan=en-US&amp;anchor=BioNTech+SE&amp;index=1&amp;md5=1b483074285e1f354b050f382ec03fb3">BioNTech SE</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>, "BioNTech"))) and <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.bms.com%2F&amp;esheet=54263388&amp;newsitemid=20250602838823&amp;lan=en-US&amp;anchor=Bristol+Myers+Squibb&amp;index=2&amp;md5=83c6c6eeb4378c5bb6d68c8e39efc4ff">Bristol Myers Squibb</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>, "BMS"))) today announced that the companies have entered into an agreement for the global co-development and co-commercialization of BioNTech's investigational bispecific antibody BNT327 across numerous solid tumor types. Under the agreement, BioNTech and BMS will work jointly to broaden and accelerate the development of this clinical candidate.

News

BNTX

BioNTech And Bristol Myers Squibb Partner To Advance Bispecific Antibody BNT327 For Solid Tumors

Mizuho analyst Ben Chaiken upgrades Red Rock Resorts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RRR#NASDAQ">RRR</a>) from Neutral to Outperform and maintains the price target from $50 to $50.

Upgrades

Price Target

Analyst Ratings

Mizuho Upgrades Red Rock Resorts to Outperform, Maintains Price Target to $50

HC Wainwright &amp; Co. analyst Mitchell Kapoor initiates coverage on Boundless Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLD#NASDAQ">BOLD</a>) with a Buy rating and announces Price Target of $5.

Initiation

BOLD

HC Wainwright & Co. Initiates Coverage On Boundless Bio with Buy Rating, Announces Price Target of $5

HC Wainwright &amp; Co. analyst Mitchell Kapoor assumes Avalo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVTX#NASDAQ">AVTX</a>) with a Buy rating and announces Price Target of $15.

AVTX

HC Wainwright & Co. Assumes Avalo Therapeutics at Buy, Announces Price Target of $15

iShares MSCI Israel Capped Investable Market Index Fund

Reuters Reported Iran Poised To Dismiss US Nuclear Proposal, Citing Iranian Diplomat

CareTrust REIT, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTRE#NYSE">CTRE</a>) ("CareTrust" or the "Company") announced today that, together with a joint venture partner, it has acquired a portfolio of skilled nursing facilities located in the Pacific Northwest for a total purchase price of approximately $146 million, inclusive of transaction costs.
The portfolio consists of 10 facilities comprising 911 licensed beds located across Idaho, Oregon and Washington. The acquisition was completed through a joint venture arrangement entered into between CareTrust and a large third-party healthcare real estate owner. At closing, CareTrust provided common equity and preferred equity investments totaling approximately $141 million at an initial contractual yield on its combined investment in the joint venture of approximately 9.0%. The total investment amount was funded using a combination of cash on hand and a draw from the Company's revolving credit line, which brought the outstanding balance on the revolver to approximately $475 million. The joint venture has leased the facilities to two existing tenants who each have strong rent coverage on existing leased CareTrust properties and deep operating experience pursuant to new 15-year triple-net leases that include extension options and annual escalators.
Joe Callan, Senior Vice President of Investments, added, "This acquisition further underscores the favorable investment environment we are seeing and highlights CareTrust's unique ability to leverage its operator roots to grow our portfolio with high-quality tenants."
The closing of this transaction brings the Company's annual investment total to approximately $1.1 billion. Mr. Callister noted, "After a busy 2024 deploying over $1.5 billion in skilled nursing and seniors housing investments, the momentum continues in 2025. We're excited to announce this transaction after closing the Care REIT acquisition in May to highlight the concurrent opportunities in the US and UK to grow our portfolio. With our balance sheet strength, we're positioned to pursue those opportunities in both markets simultaneously."
 &nbsp;

CTRE

Caretrust REIT Acquires Portfolio Of Skilled Nursing Facilities In Pacific Northwest For About $146M, Inclusive Of Transaction Costs

HC Wainwright &amp; Co. analyst Sean Lee assumes Senseonics Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SENS#AMEX">SENS</a>) with a Buy rating and announces Price Target of $1.1.

SENS

HC Wainwright & Co. Assumes Senseonics Holdings at Buy, Announces Price Target of $1.1

Broadstone Net Lease Disclosed That Quarter-to-date, It Has Invested $83.3M, Including $54.7M In New Property Acquisitions And $28.6M In Build-to-suit Developments

Effective June 2, 2025, KORE Group Holdings, Inc. (the "Company") appointed Anthony Bellomo as Executive Vice President, Chief Financial Officer &amp; Treasurer of the Company. In connection with such appointment, on May 28, 2025, the Company informed Paul Holtz, the Company's former Executive Vice President, Chief Financial Officer &amp; Treasurer, that he would depart from such role and as an executive officer of the Company effective May 30, 2025. Mr. Holtz is expected to remain employed by the Company in an advisory capacity through June 30, 2025 to effect an orderly transition of duties. In connection with his transition services, Mr. Holtz will continue to be paid his current annual base salary through the time he remains employed, and his outstanding equity awards will continue to vest in accordance with their terms, in each case, subject to his continued employment with the Company. After the end of such transition period, Mr. Holtz will be entitled to severance payments and benefits arising from a termination Without Cause as defined in and as set forth his Employment Agreement, dated April 1, 2022, with the Company, as more fully described in the Current Report on Form 8-K filed by the Company on April 6, 2022.
 &nbsp;
Mr. Bellomo joins the Company from Mitel Networks Corporation, where he spent the last fifteen years in financial roles of increasing responsibility, including having served as Group Vice-President, Finance M&amp;A and Chief Accounting Officer since 2018. Previously, he served in a senior financial role at Onex Corporation and as Audit Manager at Deloitte &amp; Touche LLP. He is a Chartered Accountant in Ontario, Canada, Certified Public Accountant in the State of Illinois and CFA charterholder. Mr. Bellomo has a Bachelor of Mathematics and Master of Accounting from the University of Waterloo in Waterloo, Ontario, Canada.

Management

KORE

KORE Group Names Mitel Exec Anthony Bellomo as New CFO, Replacing Paul Holtz

CareTrust REIT, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTRE#NYSE">CTRE</a>) ("CareTrust") announced today the closing of a new senior unsecured term loan and the hiring of two talented real estate professionals. These actions further bolster its growth platform and strengthen the Company's long-term prospects at a time of accelerating investment in its healthcare portfolio.
New Term Loan
The Company closed on an amendment to its existing credit agreement with KeyBank National Association and a syndicate of leading financial institutions to add a new $500 million unsecured term loan (the "Term Loan") to its existing $1.2 billion unsecured revolving credit facility. The Company currently expects to use borrowings under the Term Loan to pay off the revolver balance of approximately $475 million, to fund acquisitions and for general corporate purposes. The Term Loan initially matures in May 2030, with an uncommitted accordion feature allowing for up to $800 million in additional borrowing capacity.

CareTrust REIT Closes Amendment, Enhancing Credit Facility With $500M Term Loan

B of A Securities analyst Justin Post maintains Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) with a Buy and raises the price target from $230 to $248.

AMZN

B of A Securities Maintains Buy on Amazon.com, Raises Price Target to $248

Piedmont Office Realty Trust Announced That It Has Completed Over 500,000 Square Feet Of Leasing Thus Far In The Second Quarter, With 350,000 Square Feet Related To New Tenants

VIAV

Inertial Labs, A VIAVI Solutions Announced The Launch Of A Visual-aided Inertial Navigation System (VINS) That Enables Aircraft To Maintain Accurate Flightpaths When No Reliable GPS/GNSS Signal Is Available

Liquidia Corporation&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LQDA#NASDAQ">LQDA</a>), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that Liquidia is scheduled to make its first commercial shipment of YUTREPIA&#x2122; (treprostinil) inhalation powder, marking the first time YUTREPIA will be available to be prescribed to patients at specialty pharmacies. This milestone was achieved only five business days following the U.S. Food and Drug Administration (FDA) approval of YUTREPIA on May 23, 2025, for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

LQDA

Liquidia Begins Shipping Newly Approved Yutrepia for Rare Lung Diseases Just Days After FDA OK

B of A Securities analyst Ronald Epstein upgrades Boeing (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) from Neutral to Buy and raises the price target from $185 to $260.

B of A Securities Upgrades Boeing to Buy, Raises Price Target to $260

<ul>
<li>Atacicept ORIGIN Phase 3 trial met the primary endpoint of reduction in proteinuria (UPCR) at week 36; participants receiving atacicept achieved a 46% reduction from baseline and 42% reduction compared to placebo at week 36 (p&lt;0.0001)</li>
<li>Other prespecified endpoints achieved similar or better results compared to the ORIGIN Phase 2b clinical trial — per FDA guidance, Vera is not sharing eGFR results at this time while the ORIGIN 3 placebo-controlled trial continues</li>
<li>The safety profile of atacicept was favorable, and comparable to placebo</li>
<li>Vera plans to meet with FDA in the coming weeks to discuss these results and the regulatory pathway; Vera currently plans to submit a Biologics License Application (BLA) for accelerated approval to the FDA in 4Q 2025; ORIGIN 3 trial continues with two-year results expected in 2027</li>
<li>Vera will host a conference call and webcast at 8:00 am ET on Monday, June 2 &nbsp;</li>
</ul>
BRISBANE, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) today announced that the primary endpoint was met in the ORIGIN Phase 3 trial of atacicept for the treatment of immunoglobulin A nephropathy (IgAN) in adults.
Participants treated with atacicept achieved a 46% reduction from baseline in proteinuria as measured by 24-hour urine protein-to-creatinine ratio (UPCR), with a statistically significant and clinically meaningful 42% reduction in UPCR compared to placebo (p&lt;0.0001) at week 36. For other prespecified endpoints, atacicept treatment also demonstrated results that were consistent with or better than those previously observed in the ORIGIN Phase 2b trial.1 The safety profile of atacicept in this analysis was favorable, and comparable to placebo. Vera plans to share these results with the FDA in the coming weeks, and full results will be submitted to the American Society of Nephrology Kidney Week.

VERA

Vera Therapeutics Says Atacicept ORIGIN Phase 3 Trial Meets Primary Endpoint Of Reduction In UPCR For IgAN Treatment; Vera Currently Plans To Submit BLA For Accelerated Approval To FDA In 4Q 2025

Southwest Airlines And China Airlines Group, A Taiwan-based Carrier, Are In Discussions To Create An Interline Partnership In Early 2026, With Published Connections Expected To Go On Sale Later This Year

Asset Sales

GPUS

Hyperscale Data Announced The Sale Of Its Minority Equity Interest In A Privately Held Pharmaceutical Company For Gross Proceeds Of $4.65M In Cash

HC Wainwright &amp; Co. analyst Brandon Folkes initiates coverage on Cardiol Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDL#NASDAQ">CRDL</a>) with a Buy rating and announces Price Target of $9.

CRDL

HC Wainwright & Co. Initiates Coverage On Cardiol Therapeutics with Buy Rating, Announces Price Target of $9

Press Releases

Bausch Health, Canada Inc. and the pan-Canadian Pharmaceutical Alliance Sign Letter of Intent for Public Drug Plan Coverage of (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide gel) Treatment for Acne Vulgaris

Bausch Health Announces Ortho Dermatologics 2025 ASPIRE HIGHER Scholarship Program

Bausch Health Announces Adoption of Shareholder Rights Plan

Legal

U.S. District Court Grants Summary Judgment in Favor of FDA, Salix, and Teva, and Against Norwich

Bausch Health Announces Filing of Supplement to Proxy Statement

Bausch Health Announces Launch of Solta Medical's Fraxel FTX(TM)

Bausch Health Announces Health Canada Clearance of Solta Medical's Thermage(R) FLX System

Earnings

Bausch Health Announces First Quarter 2025 Results

Xifaxan(R) (rifaximin) Treatment Following Overt Hepatic Encephalopathy (OHE) Hospitalization Associated with Reduced Risk of 30-Day OHE Rehospitalization

Comments

Bausch Health Companies

Notizie

Ultime notizie per Bausch Health Companies (NYSE:BHC) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO